Amgen’s multibillion-dollar collaboration with Novartis to jointly develop and market Amgen’s migraine-prevention treatment has resulted in both companies filing lawsuits.
The drugmakers are accusing each other of violating two collaboration agreements made in 2015 and 2017 to work together globally on Aimovig, which was approved in the U.S. in 2018.
Amgen claims Novartis breached the agreements because one of its affiliated companies was working on a competing product during the entire collaboration. Novartis claims Amgen wrongfully attempted to back out of the agreements — and that they are trying to cut Novartis out following Aimovig's successful US launch.
Read the Bloomberg coverage